Clinical trial
Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for…
NCT00123331 · Heidelberg University, Other · Completed
Key facts
| NCT number | NCT00123331 |
|---|---|
| Title | Rapamycin Use in Calcineurin Inhibitor (CNI)-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation |
| Official title | Rapamycin Use in CNI-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation |
| Lead sponsor | Heidelberg University, Other |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Heart Transplantation, Renal Failure |
| Intervention type | Drug |
| Interventions | Cyclosporine discontinuation, Rapamycin medication |
| Enrollment | 40 |
| Start date | Oct 1, 2003 |
| Completion | Apr 1, 2005 |
| First posted | Jul 22, 2005 |
| Last update posted | Aug 2, 2005 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: